Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480719 | 0.87 | HSD11B1 (0.50) | HSD11B1MEN1KMT2A | |
| SCHEMBL4487563 | 0.86 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL4481410 | 0.85 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL4482583 | 0.83 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL13932980 | 0.83 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL13932979 | 0.83 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL4490404 | 0.81 | DRD2 (0.58) | HSD11B1HTR1A | |
| SCHEMBL13932981 | 0.80 | HSD11B1 (0.52) | HSD11B1SIGMAR1 | |
| SCHEMBL13919815 | 0.79 | DRD2 (0.60) | HSD11B1HTR1A | |
| SCHEMBL4484653 | 0.79 | HSD11B1 (0.48) | HSD11B1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511141-B2 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR, INC. (US) | 2009-03-31 | — | — | US | claimed |
| US-7511141-B2 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511141-B2 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511141-B2 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060063776-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | PERSONS PAUL E | 2006-03-23 | — | — | US | disclosed |
| US-6936614-B2 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040254195-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | PERSONS PAUL E (US) | 2004-12-16 | — | — | US | disclosed |
| US-20020123499-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | SEPRACOR INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063776-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | HTR5A, OPRL1, HTR2A | HSD11B1 1871/4885MEN1 1403/4885TSHR 549/4885 |
| US-20020123499-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | HTR5A, OPRL1, HTR2A | HSD11B1 1871/4885MEN1 1403/4885TSHR 549/4885 |
| US-20040254195-A1 | Piperidine-piperazine ligands for neurotransmitter receptors | HTR5A, OPRL1, HTR2A | HSD11B1 1871/4885MEN1 1403/4885TSHR 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.